NOVO-NORDISK A-S-SPONS ADR live chart 106.382.256 % ↓ Swap Short: -3.1808 % Swap Long: -2.8597 % Sell 106.13 ↑ 25 Buy 106.38 ↑ Low: 104.42 Spread MT5 floating High: 108.58 Past performance is not a guarantee or prediction of future performance. ...
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 6 December 2024, Novo Nordisk has since 6 February 2024 repurchased a total 21,818,078 B shares at an average share price of DKK 828.33 per B share...
百亿补贴:诺和诺德(novo nordisk)诺和笔针头诺和针胰岛素针头糖尿病胰岛素注射笔诺和笔一次性诺和 诺和针6mm【5盒共35支】79元 推荐人:涛尼玛 商城:京东商城 时间:2025-01-12 23:41 收藏 赞 直达链接> 推荐理由 京东年货节红包 领最高9999元 该商品原价79元,下单1件,实付79元。近期好价,喜欢的慢友不...
Provide free Novo-Nordisk A/S (NVO) announcements on changes in the share capital, including the company's latest prospectus, new share issuance, increase and decrease of shareholders' holding, shareholders' meeting, share pledge, release of pledge and o
Novo Nordisk also agreed to acquire the asset Ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences PTE., Ltd. in 2023. The purchase price of the asset acquisition was USD 800 million with additional contingent payments of USD ...
NOVO NORDISK Price(1m / 3m / 12m): -3.3%/-20.9%/-22.1% LAST CLOSE: DKK603.7 TARGET PRICE: OVERVIEW Novo was probably the world's leading diabetes company, but nobody cares anymore. After getting their weekly T2D jab, Ozempic, approved for obesity as Wegovy in... (guest preview ends)...
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 13 September 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 12,235,249 B shares at an average share price of DKK 881.30 per B...
All relevant information about Novo Nordisk shares, their performance, dividend, stock quotes and ADRs and the many analysts covering Novo Nordisk shares.
value market share VP: Vice president; CER: Constant exchange rates; CRL: Complete Response Letter; US: United States; GHD: Growth Hormone Deficiency; GIP: Gastric inhibitory polypeptide; GLP-1: Glucagon Like Peptide 1 Note: The strategic aspirations are not a projection of Novo Nordisk's fina...
13 -- China has approved Novo Nordisk's semaglutide injection for use with another medical condition in addition to type-2 diabetes and weight loss. The Danish pharmaceutical giant’s application for the drug to be used for a new indication has been given the green light, the China Nation...